顺铂联合化疗对非精原细胞瘤性睾丸癌患者肾功能的某些影响。

Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma.

作者信息

Meijer S, Sleijfer D T, Mulder N H, Sluiter W J, Marrink J, Koops H S, Brouwers T M, Oldhoff J, van der Hem G K, Mandema E

出版信息

Cancer. 1983 Jun 1;51(11):2035-40. doi: 10.1002/1097-0142(19830601)51:11<2035::aid-cncr2820511113>3.0.co;2-8.

DOI:10.1002/1097-0142(19830601)51:11<2035::aid-cncr2820511113>3.0.co;2-8

PMID:6340821

Abstract

Renal function in 24 patients with disseminated nonseminomatous testicular carcinoma treated with combination chemotherapy including cis-platinum was examined prospectively. Renal function was monitored by several determinations of glomerular filtration rate (GFR), effective renal plasma flow (ERPF) and serum creatinine, and beta-2-microglobulin. A reduction in GFR and ERPF was found at the end of the induction chemotherapy and at six weeks thereafter. Median GFR and ERPF decreased both 23% (P less than 0.01). Serum creatinine and beta-2-microglobulin concentrations however did not rise. It is suggested that under the influence of chemotherapy with platinum the production of creatinine and beta-2-microglobulin is decreased rendering their serum levels unsuitable as parameters of renal function.

摘要

对24例接受含顺铂联合化疗的播散性非精原细胞瘤性睾丸癌患者的肾功能进行了前瞻性研究。通过多次测定肾小球滤过率（GFR）、有效肾血浆流量（ERPF）、血清肌酐和β2-微球蛋白来监测肾功能。诱导化疗结束时及之后六周发现GFR和ERPF降低。GFR和ERPF的中位数均下降了23%（P<0.01）。然而，血清肌酐和β2-微球蛋白浓度并未升高。提示在铂类化疗的影响下，肌酐和β2-微球蛋白的生成减少，使其血清水平不适宜作为肾功能参数。